11 DESCRIPTION

One-third to one-half of the subjects in these studies reported successful intercourse at least once during a 4-week, treatment-free run-in period.

• Often, OTC Sildenafil is marketed with false claims of "all natural" ingredients.
• OTC drugs containing Sildenafil are sometimes used as party drugs for ED enhancement.
• Many countries have strict regulations banning OTC Sildenafil sales.
• OTC Sildenafil can trigger dangerous hypotension in some users.
• Users should avoid OTC Sildenafil if they are taking medications affecting blood flow.
• OTC Sildenafil’s unregulated status increases the risk of adverse effects.
• Proper dosage information is essential but often missing on OTC products.
• OTC Sildenafil should be purchased from reputable sources to ensure safety.
• Doctors warn against using OTC Sildenafil without proper diagnosis.
• Long-term health effects of OTC Sildenafil are still under study.
• OTC Sildenafil misuse can lead to serious health emergencies.

In many of the studies, of both fixed dose and titration designs, daily diaries were kept by patients.

• Herbal supplements claiming to contain Sildenafil often have inconsistent quality.
• OTC Sildenafil products sometimes contain fillers or undisclosed ingredients.
• Many OTC "performance enhancers" include Sildenafil as an unapproved additive.
• Users should research the manufacturer before buying OTC Sildenafil products.
• OTC Sildenafil may be combined with other performance ingredients, increasing risk.
• Effects of OTC Sildenafil can vary based on individual health factors.
• OTC products often lack clinical trial evidence supporting efficacy.
• OTC Sildenafil is sometimes promoted through social media influencers.
• Long-term safety of OTC Sildenafil products remains largely unstudied.
• OTC Sildenafil can cause side effects, especially if user has underlying health issues.
• Check for lab testing or certification when selecting OTC Sildenafil products.

In these studies, involving about 1600 patients, analyses of patient diaries showed no effect of VIAGRA on

• OTC Sildenafil is sometimes illegally imported or sold without license.
• Many OTC Sildenafil products are marketed directly to consumers via online ads.
• Beware of overly attractive pricing on OTC Sildenafil products.
• OTC Sildenafil may cause dangerous interactions with other pharmaceuticals.
• There are ongoing efforts to crack down on illegal OTC Sildenafil sales.
• Some OTC formulations are designed to look like prescription medications.
• Use of OTC Sildenafil should be avoided by individuals with health conditions.
• OTC Sildenafil products may contain harmful contaminants if unregulated.
• The efficacy of OTC Sildenafil varies greatly between products.
• OTC Sildenafil's safety can be compromised by poor manufacturing practices.
• Always verify OTC Sildenafil's legitimacy before use.

rates of attempted intercourse (about 2 per week), but there was clear treatment-related improvement in sexual function: per

12.2 Pharmacodynamics

VIAGRA was effective in a broad range of ED patients, including those with a history of coronary artery disease, hypertension, other cardiac disease, peripheral vascular disease, diabetes mellitus, depression, coronary artery bypass graft (CABG), radical prostatectomy, transurethral resection of the prostate (TURP) and spinal cord injury, and in patients taking antidepressants/antipsychotics and anti-hypertensives/diuretics. In clinical studies, VIAGRA was assessed for its effect on the ability of men with erectile dysfunction (ED) to engage in sexual activity and in many cases specifically on the ability to achieve and maintain an erection sufficient for satisfactory sexual activity. The studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with placebo. The effectiveness of VIAGRA was evaluated in most studies using several assessment instruments. In addition, patients were asked a global efficacy question and an optional partner questionnaire was administered.

Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately:

The effect on one of the major end points, maintenance of erections after penetration, is shown in Figure 6, for the pooled results of 5 fixed-dose, dose-response studies of greater than one month duration, showing response according to baseline function. At the same time, on-treatment function was better in treated patients who were less impaired at baseline. The frequency of patients reporting improvement of erections in response to a global question in four of the randomized, double-blind, parallel, placebo-controlled fixed dose studies (1797 patients) of 12 to 24 weeks duration is shown in Figure 7. In the titration studies (n=644) (with most patients eventually receiving 100 mg), results were similar. The patients in studies had varying degrees of ED. patient weekly success rates averaged 1.3 on 50–100 mg of VIAGRA vs 0.4 on placebo; similarly, group mean

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	150mg	10 Pills	36.73€ 34.98€	Buy
Kamagra Soft Tabs	100mg	84 + 4 Pills	233.05€ 221.95€	Buy
Viagra Generic	200mg	30 + 2 Pills	83.07€ 79.11€	Buy
Viagra Generic	25mg	10 Pills	25.19€ 23.99€	Buy
Kamagra Polo	100mg	84 + 4 Pills	244.49€ 232.85€	Buy
Viagra Generic	50mg	270 + 8 Pills	198.48€ 189.03€	Buy
Kamagra Polo	100mg	180 + 8 Pills	446.52€ 425.26€	Buy
Kamagra Soft Tabs	100mg	272 + 12 Pills	593.42€ 565.16€	Buy
Viagra Generic	150mg	60 + 4 Pills	111.25€ 105.95€	Buy
Viagra Generic	100mg	20 Pills	45.58€ 43.41€	Buy
Viagra Generic	100mg	270 + 10 Pills	270.47€ 257.59€	Buy
Viagra Generic	100mg	10 Pills	28.91€ 27.53€	Buy
Viagra Generic	50mg	20 Pills	40.52€ 38.59€	Buy

success rates (total successes divided by total attempts) were about 66% on VIAGRA vs about 20% on placebo.

Access to Medication

At the end of the long-term study, 88% of patients reported that VIAGRA improved their erections.Men with untreated ED had relatively low baseline scores for all aspects of sexual function measured (again using a 5-point scale) in the IIEF. VIAGRA improved these aspects of sexual function: frequency, firmness and maintenance of erections; frequency of orgasm; frequency and level of desire; frequency, satisfaction and enjoyment of intercourse; and overall relationship satisfaction.One randomized, double-blind, flexible-dose, placebo-controlled study included only patients with erectile dysfunction attributed to complications of diabetes mellitus (n=268). As in the other titration studies, patients were started on 50 mg and allowed to adjust the dose up to 100 mg or down to 25 mg of VIAGRA; all patients, however, were receiving 50 mg or 100 mg at the end of the study. There were highly statistically significant improvements on the two principal IIEF questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) on VIAGRA compared to placebo. On a global improvement question, 57% of VIAGRA patients reported improved erections versus 10% on placebo.

How it works

Diary data indicated that on VIAGRA, 48% of intercourse attempts were successful versus 12% on placebo.One randomized, double-blind, placebo-controlled, crossover, flexible-dose (up to 100 mg) study of patients with erectile dysfunction resulting from spinal cord injury (n=178) was conducted. The changes from baseline in scoring on the two end point questions (frequency of successful penetration during sexual activity and maintenance of erections after penetration) were highly statistically significantly in favor of VIAGRA. On a global improvement question, 83% of patients reported improved erections on VIAGRA versus 12% on placebo. Diary data indicated that on VIAGRA, 59% of attempts at sexual intercourse were successful compared to 13% on placebo.Across all trials, VIAGRA improved the erections of 43% of radical prostatectomy patients compared to 15% on placebo.Subgroup analyses of responses to a global improvement question in patients with psychogenic etiology in two fixed-dose studies (total n=179) and two titration studies (total n=149) showed 84% of VIAGRA patients reported improvement in erections compared with 26% of placebo. Diary data in two of the studies (n=178) showed rates of successful intercourse per attempt of 70% for sildenafil syrup VIAGRA and 29% for placebo.Efficacy Results in Subpopulations in Controlled Clinical StudiesA review of population subgroups demonstrated efficacy regardless of baseline severity, etiology, race and age. During 3 to 6 months of double-blind treatment or longer-term (1 year), open-label studies, few patients withdrew from active treatment for any reason, including lack of effectiveness. At the end of the long-term study, 88% of patients reported that VIAGRA improved their erections.

Side Effect	Frequency	Severity	Recommended Action
Headache	Common	Mild	Hydration, OTC pain relievers
Flushing	Common	Mild	Cooling measures
Nasal Congestion	Common	Mild	Decongestants, if needed
Dizziness	Less Common	Moderate	Avoid driving, sit or lie down

Men with untreated ED had relatively low baseline scores for all aspects of sexual function measured (again using a 5-point scale) in the IIEF.

• Overuse of OTC Sildenafil can lead to unwanted side effects and health risks.
• OTC Sildenafil is not approved by medical authorities for general use.
• Pharmacovigilance agencies monitor adverse effects from OTC Sildenafil.
• OTC Sildenafil may contain other undisclosed active substances.
• Always check for proper labeling when purchasing OTC Sildenafil.
• OTC Sildenafil should not be used as a recreational drug.
• Consumers should be aware of potential health hazards of OTC Sildenafil.
• OTC Sildenafil may impair blood pressure regulation in some users.
• Regular use of OTC Sildenafil without medical oversight is risky.
• Using OTC Sildenafil with alcohol can increase side effects.
• OTC Sildenafil is often advertised with exaggerated claims of effectiveness.

VIAGRA improved these aspects of sexual function: frequency, firmness and maintenance of erections; frequency of

2.2 Use with Food

VIAGRA demonstrated statistically significant improvement compared to placebo in all 21 studies. The studies that established benefit demonstrated improvements in success rates for sexual intercourse compared with placebo.Efficacy Endpoints in Controlled Clinical StudiesThe effectiveness of VIAGRA was evaluated in most studies using several assessment instruments. The primary measure in the principal studies was a sexual function questionnaire (the International Index of Erectile Function - IIEF) administered during a 4-week treatment-free run-in period, at baseline, at follow-up visits, and at the end of double-blind, placebo-controlled, at-home treatment. Two of the questions from the IIEF served as primary study endpoints; categorical responses were elicited to questions about (1) the ability to achieve erections sufficient for sexual intercourse and (2) the maintenance of erections after penetration. The patient addressed both questions at the final visit for the last 4 weeks of the study.

What Are Causes of Erectile Dysfunction?

The possible categorical responses to these questions were (0) no attempted intercourse, (1) never or almost never, (2) a few times, (3) sometimes, (4) most times, and (5) almost always or always. Also collected as part of the IIEF was information about other aspects of sexual function, including information on erectile function, orgasm, desire, satisfaction with intercourse, and overall sexual satisfaction. Sexual function data were also recorded by patients in a daily diary. In addition, patients were asked a global efficacy question and an optional partner questionnaire was administered.Efficacy Results from Controlled Clinical StudiesThe effect on one of the major end points, maintenance of erections after penetration, is shown in Figure 6, for the pooled results of 5 fixed-dose, dose-response studies of greater than one month duration, showing response according to baseline function. Results with all doses have been pooled, but scores showed greater improvement at the 50 and 100 mg doses than at 25 mg. orgasm; frequency and level of desire; frequency, satisfaction and enjoyment of intercourse; and overall relationship satisfaction.

12.3 Pharmacokinetics

The pattern of responses was similar for the other principal question, the ability to achieve an erection sufficient for intercourse. The titration studies, in which most patients received 100 mg, showed similar results. Figure 6 shows that regardless of the baseline levels of function, subsequent function in patients treated with VIAGRA was better than that seen in patients treated with placebo. At the same time, on-treatment function was better in treated patients who were less impaired at baseline.The frequency of patients reporting improvement of erections in response to a global question in four of the randomized, double-blind, parallel, placebo-controlled fixed dose studies (1797 patients) of 12 to 24 weeks duration is shown in Figure 7. These patients had erectile dysfunction at baseline that was characterized by median categorical scores of 2 (a few times) on principal IIEF questions.

Kamagra Oral Jelly

Erectile dysfunction was attributed to organic (58%; generally sildenafil 100 mg tab not characterized, but including diabetes and excluding spinal cord injury), psychogenic (17%), or mixed (24%) etiologies. Sixty-three percent, 74%, and 82% of the patients on 25 mg, 50 mg and 100 mg of VIAGRA, respectively, reported an improvement in their erections, compared to 24% on placebo. In the titration studies (n=644) (with most patients eventually receiving 100 mg), results were similar.The patients in studies had varying degrees of ED. One-third to one-half of the subjects in these studies reported successful intercourse at least once during a 4-week, treatment-free run-in period.In many of the studies, of both fixed dose and titration designs, daily diaries were kept by patients. In these studies, involving about 1600 patients, analyses of patient diaries showed no effect of VIAGRA on rates of attempted intercourse (about 2 per week), but there was clear treatment-related improvement in sexual function: per patient weekly success rates averaged 1.3 on 50–100 mg of VIAGRA vs 0.4 on placebo; similarly, group mean success rates (total successes divided by total attempts) were about 66% on VIAGRA vs about 20% on placebo.During 3 to 6 months of double-blind treatment or longer-term (1 year), open-label studies, few patients withdrew from active treatment for any reason, including lack of effectiveness.